Novo Holdings A/S
Novo Holdings A/S reported 25 holdings worth US$1.72B as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
Novo Holdings A/S reported 25 holdings worth US$1.72B as of Jun 30, 2026. Largest: Edgewise Therapeutics, Inc., Asml Holding Nv and Hemab Therapeutics Holdings, Inc. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 25
- Value as reported
- US$1.72B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Edgewise Therapeutics, Inc. | 5.35M | US$217M | 12.6% |
| Asml Holding Nv | 94,946 | US$189M | 11.0% |
| Hemab Therapeutics Holdings, Inc. | 4.18M | US$154M | 8.9% |
| Brookfield Corporation | 3.5M | US$150M | 8.7% |
| Maplight Therapeutics, Inc. | 3.69M | US$132M | 7.7% |
| Mirum Pharmaceuticals, Inc. | 1.13M | US$132M | 7.6% |
| Avalyn Pharma Inc. | 3.88M | US$128M | 7.4% |
| Salesforce, Inc. | 393K | US$61.6M | 3.6% |
| Arrivent Biopharma, Inc. | 1.5M | US$52.1M | 3.0% |
| Enliven Therapeutics, Inc. | 1M | US$50.8M | 2.9% |
| Crinetics Pharmaceuticals, Inc. | 1.32M | US$49.4M | 2.9% |
| Floor & Decor Holdings, Inc. | 797K | US$47.3M | 2.7% |
| Vaxcyte, Inc. | 800K | US$46.5M | 2.7% |
| 4d Molecular Therapeutics, Inc. | 3.25M | US$43.2M | 2.5% |
| Viridian Therapeutics, Inc. | 2.13M | US$39.2M | 2.3% |
| Celldex Therapeutics, Inc. | 1.02M | US$38.1M | 2.2% |
| Alumis Inc. | 1.1M | US$31M | 1.8% |
| Xenon Pharmaceuticals Inc. | 485K | US$29.3M | 1.7% |
| Dyne Therapeutics, Inc. | 960K | US$21.3M | 1.2% |
| Bridgebio Oncology Therapeutics, Inc. | 2.25M | US$17.1M | 1.00% |
| Insmed Incorporated | 121K | US$12.9M | 0.75% |
| Marqeta, Inc. | 442K | US$7.17M | 0.42% |
| Lanzatech Global, Inc. | 158K | US$1.08M | 0.06% |
| Apogee Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Biomarin Pharmaceutical Inc. | 0 | US$0 | 0.00% |
| Valneva Se | 0 | US$0 | 0.00% |
Source
View original at SEC
Related